Seeking Alpha

Takeda Pharmaceutical Co., Ltd. (TKPHF)

- OTCPK - Current
  • Mon, Mar. 23, 7:47 AM
    • Takeda Pharmaceutical (OTCPK:TKPHF) (OTCPK:TKPYY), through its Millennium Pharmaceuticals subsidiary, licenses exclusive rights to use ImmunoGen's (NASDAQ:IMGN) antibody-drug conjugate (ADC) technology to develop and commercialize targeted cancer therapeutics for up to two undisclosed targets, with an option for a third target for an additional upfront fee.
    • Under the terms of the agreement, ImmunoGen will receive $20M upfront for each target, milestones up to $210M and royalties on net commercial sales of any resulting products.
    • An antibody-drug conjugate is a cytotoxic agent attached to an antibody that binds to a target antigen found on cancer cells. This delivers the agent specifically to the cancer cells where it kills them.
    • IMGN is up 23% premarket on robust volume.
    | 1 Comment
  • Tue, Mar. 3, 1:03 PM
    • Orexigen Therapeutics (OREX +53%) short sellers are licking their wounds today. Shares are up on a whopping 22x surge in volume in response to the news that patients taking its obesity med Contrave (naltrexone HCl/bupropion HCl) may reduce their risk of having a heart attack by almost 50%.
    • The data behind the news comes from an interim analysis of the 9,000-patient LIGHT study which is being conducted to determine the heart-safety profile of the obesity med. The analysis showed patients receiving Contrave experienced 35 major adverse cardiac events (MACE) compared to 59 for those taking placebo. The benefit was statistically significant. A MACE is a heart attack, stroke or heart-related death.
    • The company will conduct a second interim analysis of the data at 50% of events, which should happen in the next several weeks. Orexigen is also required to run a second heart-safety study as a condition of its clearance by the FDA in September 2014.
    • Contrave is sold in the U.S. by Takeda Pharmaceutical Co. (OTCPK:TKPHF) (OTCPK:TKPYY).
    • According to Yahoo Finance, almost 42% of Orexigen's float (more than 38M shares) was sold short as of February 13.
    • Related tickers: (VVUS +4.3%)(ARNA -5.5%)
  • Dec. 8, 2014, 12:37 PM
    • Biotech investors are giving Seattle Genetics (SGEN -8.4%) the cold shoulder today on increased volume. It appears that all the love is being directed to the potential of competitors' PD-1 inhibitors in fighting cancer despite the company's presentations at the American Society of Hematology meeting of positive results for Adcetris (brentuximab vedotin), an antibody-drug conjugate directed to CD30 in Hodgkin lymphoma (HL).
    • Long-term data from a Phase 1 trial of Adcetris combined with AVD (adriamycin, vinblastine, dacarbazine) demonstrated a 100% overall survival rate at year three and 92% failure-free survival rate at year 3 in frontline HL.
    • Adcetris in combination with bendamustine as a second-line therapy demonstrated an objective response rate of 96% and a complete remission rate of 83% in patients with relapsed or refractory HL.
    • In a Phase 2 trial in previously untreated HL patients aged 60 and older, Adcetris showed a 93% objective response rate.
    • The company is collaborating with Takeda Pharmaceutical Co. (OTCPK:TKPHF) (OTCPK:TKPYY) on the development of the product.
    • Previously: Positive results in Adcetris Phase 3 label expansion trial (Sept. 29, 2014)
    • PD-1 inhibitor-related tickers: (BMY +0.2%)(FPRX +4.8%)(MRK -0.2%)(CELG +4.2%)(OTCQX:RHHBY -0.5%)(AZN -0.6%)
    | 1 Comment
  • Dec. 27, 2013, 7:51 AM
    • "The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.
    • The drug was tied to liver damage.
    • The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.
    • Shares fell 5%+ in Tokyo on the news.
    | Comment!
  • Oct. 7, 2013, 8:41 AM
    • Apricus Biosciences (APRI) gets national phase approval (the company's fifth) in Germany for Vitaros.
    • The company says the five remaining European phase approvals should be obtainable in Q4 and Q1 2014.
    • Vitaros' application for marketing approval is approved under the Decentralized Procedure. The Netherlands is the RMS.
    • APRI has multiple partners for the ED treatment including Takeda (TKPHF.PK), Sandoz, and Abbott (ABT). (PR)
    • APRI +10% premarket.
    | Comment!
  • Jun. 10, 2013, 7:37 AM
    Via the European Decentralized Procedure (Netherlands is the Reference Member State), Apricus (APRI) gets its ED treatment Vitaros approved. The company believes it will "capture a significant share of the ~$1B PDE-5 inhibitor market." APRI says it will work with partners Sandoz, Takeda (TKPHF.PK), and Bracco to obtain national phase approvals. Shares +9.38% premarket. (PR)
    | Comment!
  • Apr. 23, 2013, 8:07 AM
    Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket.
    | 1 Comment
  • Sep. 13, 2012, 9:22 AM
    Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros.
    | 1 Comment
  • Jun. 22, 2012, 9:03 AM
    NPS Pharmaceuticals (NPSP) +8.3% premarket after the company and drug partner Takeda (TKPHF.PK) say a European panel recommended their Revestive drug receive marketing approval as a once-daily treatment for adults with short bowel syndrome.
    | Comment!
Visit Seeking Alpha's
TKPHF vs. ETF Alternatives
Company Description
Research & Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.
Country: Japan